Previous Close | 10.25 |
Open | 9.95 |
Bid | 9.10 |
Ask | 11.15 |
Strike | 33.00 |
Expire Date | 2026-01-16 |
Day's Range | 9.95 - 10.57 |
Contract Range | N/A |
Volume | |
Open Interest | 120 |
PRINCETON, N.J., June 03, 2024--Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations...
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.